ONCOTHERAPEUTICS PLANS PHASE II OTx-287 STUDIES IN RENAL, COLORECTAL
Executive Summary
ONCOTHERAPEUTICS PLANS PHASE II OTx-287 STUDIES IN RENAL, COLORECTAL and either brain or melanoma cancers in the next 12 to 18 months, Exec VP-R&D Frank Pilkiewicz, PhD, told a Mabon Securities conference on cell therapy, gene therapy and drug delivery companies in New York City Feb. 16. Pilkiewicz described OTx-287 as a "proteo-liposome formulation" of interleukin-2. Recombinant IL-2 is marketed by Chiron for treatment of metasiatic renal cell carcinoma as Proleukin.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth